Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Read full article: Expect roller coaster temps plus rounds of rain for the next 7 days The Annual State of the County Address for Botetourt County is set to be held Thursday at 8 a.m. Read full ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with ...

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.